CCL2 and neoplasm: Our in vivo experiments demonstrated that disrupting the tumor‐adipose tissue feedback loop with nAb‐CCL2 not only inhibited tumor growth but also decreased lipolysis in tumor‐adjacent adipose tissue, thereby preserving its volume in the HFD group.